Patients undergoing dialysis for the treatment of end-stage-renal disease contribute to the high number of cardiac-related mortality cases in the nation due to the tendency to develop vascular calcification. The longevity of dialysis treatment and food restrictions associated with severe renal failure often result in deficiency of a naturally occurring chelating proteins and dietary vitamin K. Chelating proteins function to bind with calcium and arrest mineral growth in the extracellular space by forming soluble complexes, then facilitating in their removal from arterial tissue and vitamin K2 promotes heart health by activating specific smooth muscle cell proteins, which prevent vascular calcification.  The primary focus of this research is to utilize the native circulatory system to deliver a protein-based therapy to calcified arteries via stimuli-responsive polymer vehicles in a minimally invasive manner to treat vascular calcification in high-risk patient groups.